WO2016140353A1 - 安定した表現型を示す疾患モデルブタおよびその作製方法 - Google Patents
安定した表現型を示す疾患モデルブタおよびその作製方法 Download PDFInfo
- Publication number
- WO2016140353A1 WO2016140353A1 PCT/JP2016/056865 JP2016056865W WO2016140353A1 WO 2016140353 A1 WO2016140353 A1 WO 2016140353A1 JP 2016056865 W JP2016056865 W JP 2016056865W WO 2016140353 A1 WO2016140353 A1 WO 2016140353A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pig
- gene
- offspring
- genetically modified
- disease model
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 76
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- 230000001747 exhibiting effect Effects 0.000 title abstract description 6
- 210000004027 cell Anatomy 0.000 claims abstract description 49
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 47
- 230000014639 sexual reproduction Effects 0.000 claims abstract description 38
- 208000026350 Inborn Genetic disease Diseases 0.000 claims abstract description 29
- 208000016361 genetic disease Diseases 0.000 claims abstract description 29
- 231100000518 lethal Toxicity 0.000 claims abstract description 20
- 230000001665 lethal effect Effects 0.000 claims abstract description 20
- 210000004602 germ cell Anatomy 0.000 claims abstract description 17
- 238000012239 gene modification Methods 0.000 claims abstract description 16
- 230000005017 genetic modification Effects 0.000 claims abstract description 14
- 235000013617 genetically modified food Nutrition 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 71
- 238000000034 method Methods 0.000 claims description 56
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 claims description 24
- 206010012601 diabetes mellitus Diseases 0.000 claims description 23
- 238000012546 transfer Methods 0.000 claims description 22
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 20
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 20
- 206010020575 Hyperammonaemia Diseases 0.000 claims description 20
- 108010083379 Sarcoglycans Proteins 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 18
- 210000002149 gonad Anatomy 0.000 claims description 17
- 108020004485 Nonsense Codon Proteins 0.000 claims description 16
- 210000000805 cytoplasm Anatomy 0.000 claims description 12
- 230000013011 mating Effects 0.000 claims description 12
- 210000003855 cell nucleus Anatomy 0.000 claims description 11
- 230000037434 nonsense mutation Effects 0.000 claims description 6
- 230000000392 somatic effect Effects 0.000 claims description 5
- 210000005132 reproductive cell Anatomy 0.000 claims description 3
- 102000009824 Hepatocyte Nuclear Factor 1-alpha Human genes 0.000 claims 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 claims 1
- 241000282887 Suidae Species 0.000 abstract description 29
- 210000004291 uterus Anatomy 0.000 abstract description 4
- 238000010449 nuclear transplantation Methods 0.000 abstract 4
- 238000009402 cross-breeding Methods 0.000 abstract 3
- 210000004907 gland Anatomy 0.000 abstract 1
- 230000001850 reproductive effect Effects 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 description 103
- 210000001082 somatic cell Anatomy 0.000 description 32
- 206010064571 Gene mutation Diseases 0.000 description 20
- 238000010370 cell cloning Methods 0.000 description 19
- 101150057876 OTC gene Proteins 0.000 description 17
- 235000013601 eggs Nutrition 0.000 description 15
- 101150087412 Sgcd gene Proteins 0.000 description 14
- 210000001766 X chromosome Anatomy 0.000 description 14
- 230000007812 deficiency Effects 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 12
- 238000010459 TALEN Methods 0.000 description 12
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 11
- 210000004940 nucleus Anatomy 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000000969 carrier Substances 0.000 description 10
- 210000002257 embryonic structure Anatomy 0.000 description 10
- 210000001550 testis Anatomy 0.000 description 10
- 230000001973 epigenetic effect Effects 0.000 description 9
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 102100021790 Delta-sarcoglycan Human genes 0.000 description 7
- 101000616408 Homo sapiens Delta-sarcoglycan Proteins 0.000 description 7
- 108700005079 Recessive Genes Proteins 0.000 description 7
- 102000052708 Recessive Genes Human genes 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 108700024394 Exon Proteins 0.000 description 6
- 210000004681 ovum Anatomy 0.000 description 6
- 230000009261 transgenic effect Effects 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000010362 genome editing Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000001568 sexual effect Effects 0.000 description 5
- 230000002381 testicular Effects 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 210000002459 blastocyst Anatomy 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 210000003765 sex chromosome Anatomy 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 102000019344 Gamma-sarcoglycan Human genes 0.000 description 3
- 101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 description 3
- 210000001109 blastomere Anatomy 0.000 description 3
- 230000012173 estrus Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108700003861 Dominant Genes Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 230000035938 sexual maturation Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000019326 Delta-sarcoglycan Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001035782 Gallus gallus Hemoglobin subunit beta Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108700005090 Lethal Genes Proteins 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101710113020 Ornithine transcarbamylase, mitochondrial Proteins 0.000 description 1
- 108010005991 Pork Regular Insulin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000011257 dilated cardiomyopathy 1B Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 208000004996 familial dilated cardiomyopathy Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 244000000003 plant pathogen Species 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0273—Cloned vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8778—Swine embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1018—Carboxy- and carbamoyl transferases (2.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/03—Carboxy- and carbamoyltransferases (2.1.3)
- C12Y201/03003—Ornithine carbamoyltransferase (2.1.3.3)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
Definitions
- the present invention relates to a disease model pig showing a stable phenotype and a method for producing the same.
- the present invention also relates to a chimeric pig, its gonad and its germ cell for producing a disease model pig exhibiting a stable phenotype.
- genetically modified animals can be produced by somatic cell cloning technology from mammalian cells in which the function of a specific gene is modified using genome editing technology, gene disruption technology, or the like (Non-patent Document 1). ⁇ 4).
- a phenotype derived from a disease responsible gene is not always stably obtained. This is a cause of greatly reducing the attractiveness of producing genetically modified animals by somatic cell cloning technology.
- the present invention provides a disease model pig showing a stable phenotype and a method for producing the same.
- the present invention also provides a chimeric pig, its gonad and its germ cell for producing a disease model pig exhibiting a stable phenotype.
- the present inventors have solved the problem that the phenotype is unstable in genetically modified pigs produced by somatic cell cloning, and eliminating the epigenetic effects derived from somatic cells. They found that genetically modified pigs with stable phenotypes can be obtained. The present inventors have also found that a hyperammonemia model pig can be produced by disrupting the function of the ornithine transcarbamylase gene. The present inventors further found that a model pig with dilated cardiomyopathy can be produced by disrupting the function of the ⁇ -sarcoglycan gene. We also devised a method to reduce epigenetic effects in these model pigs. Furthermore, the present inventors have found that it is useful to produce a chimeric embryo in order to produce a disease model pig showing a stable phenotype even if the gene to be modified is lethal. The present invention is based on these findings and inventions.
- the present invention provides the following inventions.
- a method for producing a genetically modified disease model pig (A) nuclear transfer into the egg cytoplasm using the genetically modified cell nucleus; (B) generating the resulting cloned embryo in the womb of a sow to obtain a pup; (C) mating the obtained offspring or subjecting it to sexual reproduction to obtain a further offspring genetically modified as a disease model pig; Including a method.
- the disease model pig is a disease model pig selected from the group consisting of diabetes, hyperammonemia and dilated cardiomyopathy.
- the disease model pig is a diabetes model animal, and the cells used in (a) above are cells genetically modified by introducing a dominant negative mutant of HNF-1 ⁇ (2) The method described in 1.
- a method of producing a lethal genetic disease model pig (I) nuclear transfer into the egg cytoplasm using the genetically modified cell nucleus; (Ii) a cloned embryo obtained by nuclear transfer is made into a chimeric state with a pig embryo that does not develop a genetic disease, and is generated in the womb of a sow to obtain a litter; (Iii) crossing the obtained offspring or subjecting the obtained reproductive cells to sexual reproduction to obtain a female offspring having the genetic modification; (Iv) mating the resulting female offspring with a male pig or subjecting to sexual reproduction to obtain a lethal genetic disease model pig.
- a lethal genetic disease model pig obtained by the method according to any one of (7) to (9) above.
- a genetically modified pig having a cell having an ornithine transcarbamylase gene with a disrupted gene function and a cell having a wild-type ornithine transcarbamylase gene in a somatic chimera state.
- a female pig having a heterozygous ornithine transcarbamylase gene obtained by sexual reproduction from the pig according to (13), wherein the gene function is disrupted.
- a male pig which is a model of hyperammonemia, obtained by sexual reproduction from the female pig according to (14).
- a male pig which is a model of dilated cardiomyopathy having a ⁇ -sarcoglycan gene homozygously obtained from sexual reproduction from the sow described in (19) and having a disrupted gene function.
- Gonad or germ cells obtained by the following method: (I) nuclear transfer into the egg cytoplasm using the genetically modified cell nucleus; (Ii) a cloned embryo obtained by nuclear transfer is made into a chimeric state with a pig embryo that does not develop a genetic disease, and is generated in the womb of a sow to obtain a litter; (Iii-a) A method comprising growing the obtained offspring to obtain a gonad or germ cell.
- the gene-modified cell is a cell in which the gene function of the ornithine transcarbamylase gene is disrupted, or the gene function of the ⁇ -sarcoglycan gene is disrupted.
- FIG. 1 is a graph showing changes over time in blood glucose levels of five pigs obtained by somatic cell cloning using the nuclei of genetically modified cells.
- FIG. 2 is a graph showing changes in blood glucose levels over time in next-generation offspring produced by subjecting pigs obtained by somatic cell cloning to sexual reproduction (mating).
- the offspring Tg represents the next generation offspring of genetically modified pigs obtained by somatic cell cloning, and the non-Tg offspring shows pigs that have not been genetically modified.
- FIG. 1 is a graph showing changes over time in blood glucose levels of five pigs obtained by somatic cell cloning using the nuclei of genetically modified cells.
- FIG. 2 is a graph showing changes in blood glucose levels over time in next-generation offspring produced by subjecting pigs obtained by somatic cell cloning to sexual reproduction (mating).
- the offspring Tg represents the next generation offspring of genetically modified pigs obtained by somatic cell cloning,
- FIG. 3 is a diagram showing the structure of the ornithine transcarbamylase (OTC) gene on the porcine sex chromosome (X chromosome) and a technique for modifying the OTC gene using a genome editing technique.
- FIG. 4 shows the sequence of the modified OCT gene.
- FIG. 5 is a diagram showing the structure of a ⁇ -sarcoglycan (SGCD) gene on pig chromosome 16 and a method for modifying the SGCD gene using a genome editing technique.
- FIG. 6 shows the sequence of the modified SGCD gene.
- genetically modified means that a gene has been modified by genetic engineering techniques, and at least part or all of its function has been lost, or its function has been excessively enhanced.
- examples of the genetic modification include those caused by gene introduction and those caused by alteration of genomic genes.
- genetic modification can be performed by subjecting the nucleus of a genetically modified cell to somatic cell cloning to obtain a genetically modified offspring as a genetically modified animal.
- disease model pig means a pig that exhibits symptoms of a specific disease due to genetic modification. Although it does not specifically limit as a disease, For example, diabetes, hyperammonemia, and dilated cardiomyopathy are mentioned. In certain embodiments, the disease can be hereditary.
- somatic cell cloning refers to a technique for obtaining an individual having the same genome as a somatic cell by introducing the nucleus of the somatic cell into a fertilized egg from which the nucleus has been previously inactivated or removed. .
- somatic cell cloning In large animals, including pigs, it is known to use somatic cell cloning in generating genetically modified animals such as transgenic animals and knockout animals.
- somatic cell cloning generally, nuclei extracted from somatic cells that have differentiated into skin, tissues, or organs are transplanted into egg cells (egg cytoplasm) derived from separate bodies from which the nuclei have been removed to produce cloned embryos, and estrus. This can be done by transplanting into the womb of a foster parent, another synchronized individual.
- treating means mating a male and a female.
- subject to sexual reproduction means in vivo or in vitro, bringing a sperm and an egg into contact and fertilizing, and developing in a mother's womb to obtain a litter.
- mutant trait means that when a mutant gene and a wild-type gene are heterogeneous, a trait based on the mutant gene is expressed as a phenotype.
- inferior trait means that when a mutant gene and a wild-type gene are heterogeneous, a trait based on the mutant gene is not expressed as a phenotype.
- ornithine carbamoyltransferase is used synonymously with “ornithine transcarbamylase” and “OTC”.
- ⁇ -sarcoglycan is used synonymously with “SGCD”.
- the present inventors have found that the phenotype of the first-generation offspring obtained by somatic cell cloning is not stable in a model pig with type 3 juvenile-onset diabetes.
- the inventors have also shown that when the first generation offspring obtains further offspring (second generation) by sexual reproduction, the second generation offspring stabilizes the diabetic phenotype. I found it. This suggests that the epigenetic state characteristic of embryos, fetuses or individuals created by somatic cell cloning affects the first generation phenotype, which is not the case in the second generation. It is resolved and suggests that the phenotype based on gene mutation appears clearly.
- a method for producing a genetically modified disease model pig (A) nuclear transfer into the egg cytoplasm using the genetically modified cell nucleus; (B) generating the resulting cloned embryo in the womb of a sow to obtain a pup; (C) mating the obtained offspring or subjecting it to sexual reproduction to obtain a further offspring genetically modified as a disease model pig;
- a method is provided comprising:
- a method of genetically modifying a cell genome a method of editing by genome editing technology such as TALEN, a method of destroying a gene by homologous recombination, a method of introducing a foreign gene, and a viral vector
- TALEN genome editing technology
- a method of destroying a gene by homologous recombination a method of introducing a foreign gene
- a viral vector examples thereof include a method of modifying a gene on the genome such as a method of introducing a foreign gene.
- the modification of the cell may be performed by a method such as introducing DNA, RNA or protein into the cell without modifying the genome.
- TALEN is a hybrid enzyme that fuses the highly conserved DNA binding domain 33-35 of TALE (Transcription (Activator-Like Effector) protein derived from the plant pathogen Xanthomonas with the nuclease domain of FokI protein, and genome editing It is well known as a tool. That is, the cells may be transgenic by introducing a foreign gene by modification, or the function of the gene may be partially or wholly destroyed to be knocked out.
- TALE Transcription (Activator-Like Effector) protein derived from the plant pathogen Xanthomonas with the nuclease domain of FokI protein, and genome editing It is well known as a tool. That is, the cells may be transgenic by introducing a foreign gene by modification, or the function of the gene may be partially or wholly destroyed to be knocked out.
- genetic modification causes genetic disease.
- a gene to be introduced or a gene to be destroyed for causing a genetic disease can be appropriately selected by those skilled in the art according to a disease model to be produced.
- dominant negative mutant HNF-1 ⁇ When producing a diabetic model pig, for example, but not limited, dominant negative mutant HNF-1 ⁇ can be introduced into cells.
- the dominant negative mutant HNF-1 ⁇ human or porcine dominant negative mutant HNF-1 ⁇ can be used, and HNF-1 ⁇ P291fsinsC can be used.
- HNF-1 ⁇ P291fsinsC was discovered as a causative gene of juvenile-onset adult type diabetes, has a base sequence of SEQ ID NO: 3, and encodes a protein having the amino acid sequence of SEQ ID NO: 4.
- Human HNF-1 ⁇ is a protein having 631 amino acids, but HNF-1 ⁇ P291fsinsC has a mutation in which one base cytosine is inserted into 8 consecutive cytosines in human HNF-1 ⁇ base numbers 1091 to 1098. As shown in SEQ ID NO: 3, the 316th codon becomes a stop codon and is produced as a protein shorter than the original protein. This dominant negative mutant inhibits the normal function of HNF-1 ⁇ by overexpression and exhibits a diabetic phenotype.
- the ornithine transcarbamylase (OTC) gene can be disrupted.
- the OTC gene is present on the X chromosome, which is a sex chromosome, and is considered to be composed of 10 exons.
- the coding region of the OTC gene is as shown in SEQ ID NO: 5 at positions 42 to 1106 in the case of pigs, and the amino acid sequence is as shown in SEQ ID NO: 6.
- Disruption of the OTC gene develops hyperammonemia in males, and females that are heterozygous for wild type and mutant form carriers or develop due to additional factors.
- the destruction of the OTC gene can be performed, for example, by modifying the gene so that a nonsense codon is generated.
- the disruption of the OTC gene may be performed by modifying the first to third exons, preferably the second exon, to generate a nonsense codon.
- Such nonsense codons can be generated, for example, using genetic modification techniques such as TALEN and site-directed mutagenesis.
- TALEN is said to have a lower off-target effect of unexpected DNA cleavage (Ain et al.) Than other mutagenesis techniques (method using zinc finger nuclease (ZFN) or CRISPR / Cas9). , J Control Release (2015)).
- the sequence of the second exon in which the nonsense codon is generated is, for example, as shown in SEQ ID NO: 8, where a part of the second exon is composed of bases 109 to 113 in the base sequence of SEQ ID NO: Due to the deletion, the 64th codon in the nucleotide sequence of SEQ ID NO: 5 is changed to a nonsense codon, and the resulting amino acid has the sequence as shown in SEQ ID NO: 10.
- a ⁇ -sarcoglycan (SGCD) gene can be modified.
- the SGCD gene exists on chromosome 16 and is considered to be composed of 8 exons.
- the coding region of the SGCD gene is as shown in SEQ ID NO: 11 at 77 to 946, and the amino acid sequence is as shown in SEQ ID NO: 13.
- the SGCD gene can be disrupted by modifying the gene so that a nonsense codon is generated.
- the disruption of the OTC gene may be performed by modifying the first to third exons, preferably the second exon, to generate a nonsense codon.
- Such nonsense codons can be generated, for example, using genetic modification techniques such as TALEN and site-directed mutagenesis.
- the sequence of the second exon in which the nonsense codon is generated is as shown in SEQ ID NO: 13, where a part of the second exon is composed of bases 208 to 211 in the base sequence of SEQ ID NO: 11. Due to the deletion, the codon number 50 in the amino acid sequence of SEQ ID NO: 11 is changed to a nonsense codon, and the resulting amino acid has the sequence as shown in SEQ ID NO: 14.
- 1859 bases upstream from position 147 of the second exon of the SGCD gene shown in SEQ ID NO: 15 are deleted to give the sequence shown in SEQ ID NO: 16, thereby deleting the region containing the start codon. Also good.
- gene modification is not limited to TALEN, and may be performed using other well-known techniques such as homologous recombination and site-directed mutagenesis.
- the cells thus genetically modified are not particularly limited, but can be selected, for example, by sequencing the modified genes or expressing a selection marker.
- the selected cells are preferably cloned.
- the genetically modified cell nuclei can be subjected to somatic cell cloning.
- (B) Generating the obtained cloned embryo in the womb of a sow to obtain a pup
- the obtained cloned embryo can be generated in the womb of a sow, thereby producing a genetically modified cell.
- Offspring (genetically modified pigs) can be obtained.
- a female pig can establish pregnancy in the womb by introducing a cloned embryo into the uterus after synchronizing the estrus, and a litter can be obtained by generating a cloned embryo.
- the pig obtained in (b) is sometimes referred to as the first generation pig.
- next-generation pigs (sometimes referred to as “second-generation pigs”) can be obtained.
- next-generation pigs (sometimes referred to as “second-generation pigs”)
- a litter becomes lethal before sexual maturity, it is genetically modified by methods such as artificial insemination or in vitro fertilization after obtaining germ cells (sperm, ovum and their precursor cells) or gonads by well-known methods
- Next generation pigs can be obtained.
- Sperm may be collected, for example, from the testis or may be obtained by inducing sperm having fertilizing ability from testis tissue.
- a method for inducing sperm having fertility from testis tissue is not particularly limited, but it is known that, for example, sperm having fertility can be obtained by transplanting testis tissue subcutaneously in an immunodeficient mouse.
- the offspring obtained in (c) develops a disease and becomes a disease model pig when the modified gene has a dominant character (for example, when a dominant negative mutant is introduced).
- the modified gene is a recessive trait (including the case where the gene is on a sex chromosome and the individual is a female)
- the individual does not develop the disease and becomes a carrier of the mutant gene .
- the genetically modified gene is recessive and is present on the sex chromosome, the male develops a disease, becomes a disease model pig, and the female develops a diseased gene carrier without developing the disease. become.
- the carrier of the modified gene can be crossed between the carriers to obtain a disease model pig. The above relationship is shown in Table 1.
- the obtained offspring develops a disease
- this is used as a disease model pig, and when it becomes a carrier, the offspring that is the carrier is subjected to sexual reproduction, and the offspring that develops the disease Can get offspring.
- Examples of dominant gene mutations include disease model pigs introduced with dominant negative mutations and disease model pigs having gene mutations showing dominant traits.
- a litter having such a dominant gene mutation becomes a model pig that develops a disease.
- Examples of the gene mutation exhibiting such dominant inheritance include a dominant negative mutant of HNF-1 ⁇ , and a transgenic animal into which this mutant has been introduced becomes a model pig that develops diabetes.
- the litter becomes a model pig that develops the disease.
- Examples of genes that are present on the X chromosome and cause disease when at least part of the function is lost include the ornithine transcarbamylase (OTC) gene. When at least part of the function is lost, hyperammonemia occurs. It becomes a model pig that develops.
- OTC ornithine transcarbamylase
- the offspring becomes a carrier of genetic mutation on the X chromosome
- (c) (C)
- the resulting offspring is mated or subjected to sexual reproduction, and the further offspring genetically modified is used as a offspring having a heterogeneous gene mutation (that is, a carrier of a recessive gene mutation) Getting, And then (d) subjecting the carriers of the recessive gene mutations to sexual reproduction, subjecting the female carrier having the genetic mutation on the X chromosome to sexual reproduction, and the male offspring as a disease model pig Obtainable.
- a heterogeneous gene mutation that is, a carrier of a recessive gene mutation
- genes that are present on autosomes and cause disease when at least part or all of their functions are lost include the ⁇ -sarcoglycan (SGCD) gene.
- SGCD ⁇ -sarcoglycan
- testicular tissue is collected from the live pigs before sexual maturation, and sperm is obtained from this for mating Can be used.
- Methods for obtaining sperm from testicular tissue are well known and are not particularly limited. For example, it is known that when testicular tissue is transplanted subcutaneously in an immunodeficient mouse, fertilized sperm can be obtained. In the present invention, fertilized sperm can be obtained from testis tissue by such a method. Accordingly, in the present specification, the term “submitted to sexual reproduction” is not particularly limited as long as pups are obtained sexually, and include methods for obtaining pups from males and females by various methods. To do.
- a female in (c) above, can be obtained as a carrier among offspring having heterogeneous gene mutations (that is, carriers of recessive gene mutations).
- the disease model pig obtained as a female carrier and its offspring by (d) above can be a model that faithfully reproduces the phenotype of a human patient born from a mother who is a carrier in humans.
- a female having a genetic mutation on the X chromosome can be obtained as a carrier.
- the male disease model pig obtained as a pup by the female carrier and the above (d) can be a model that faithfully reproduces the phenotype of a human male patient born from a mother who is a carrier in humans.
- the present invention provides a male disease model pig obtained as a litter by the carrier and / or (d).
- gonad eg, testis and ovary
- reproductive Cells sperm, ovum and their progenitor cells
- a disease model pig or a carrier pig by sexual reproduction by sexual maturation, or by collecting the gonad and maturing as necessary. It is considered that the disease model pig or carrier pig thus obtained is not affected by epigenetic effects by somatic cell cloning.
- a method for producing a genetic disease model pig (I) nuclear transfer into the egg cytoplasm using the genetically modified cell nucleus; (Ii) a cloned embryo obtained by nuclear transfer is mixed with a pig embryo that does not develop a genetic disease to form a chimera, and is generated in the womb of a sow to obtain a litter; (Iii) mating the obtained offspring or subjecting the germ cells of the obtained offspring to sexual reproduction to obtain a offspring having the genetic modification;
- a method is provided comprising:
- Fatal diseases include hyperammonemia and dilated cardiomyopathy.
- a cloned embryo obtained by nuclear transfer is mixed with a pig embryo that does not develop a genetic disease to form a chimera, which is then generated in the womb of a sow to obtain a litter.
- a nucleus using somatic cells Embryos obtained by transplantation can be mixed with porcine embryos that do not develop genetic diseases, made into chimeras, and developed in the womb of sows to obtain offspring.
- the blastomere is mixed with the other embryo, and when using embryos in the blastocyst stage, the inner cell mass Can be mixed into the other embryo.
- the pig embryo that does not develop the genetic disease can be a cloned embryo obtained from a labeled cell by somatic cell cloning.
- the label is not particularly limited, and can be a label with a fluorescent protein such as, for example, wedge orange and green fluorescent protein (GFP).
- GFP wedge orange and green fluorescent protein
- a chimeric embryo is generated, for example, if it is transplanted to an estrus-synchronized borrowed female, and offspring can be obtained as a chimeric individual.
- the present invention also provides a chimeric individual thus obtained.
- Step (x) A nuclear transfer embryo (clone embryo) having a lethal gene mutation and a nuclear transfer embryo or a healthy embryo not having the gene mutation are prepared.
- any nuclear transfer embryo may be once cryopreserved.
- the litter is a chimeric individual of a pig cell that develops a genetic disease and a pig cell that does not develop the genetic disease, the symptoms of the genetic disease can be alleviated.
- germ cells sperm, ovum and their precursor cells
- gonads testis and ovary obtained from the chimeric individual obtained in step (ii).
- Such germ cells and gonads were difficult to obtain when the genetic modification was lethal.
- Such a gonad is a chimera of cells derived from a cloned embryo having a modified gene and a healthy embryo.
- the germ cells (sperm, ovum and their progenitor cells) and gonads (testis and ovary) of the present invention have genetic modifications that make the individual not alive or difficult to survive.
- the obtained offspring are mated or subjected to sexual reproduction to obtain a disease model pig having the genetic modification, and (iv) is the same as (d) above. That is, a female having a genetic mutation on the X chromosome is subjected to sexual reproduction between carriers of recessive genetic mutations or a female carrier having a genetic mutation on the X chromosome is used as a disease model pig. Can be obtained as
- the disease model pig obtained as a litter by a female carrier and said (iv) can become a model which faithfully reproduced the phenotype of a human male patient born from a mother who is a carrier in humans. Accordingly, the present invention provides a disease model pig obtained as a female carrier and / or a litter by the above (iv).
- a female having a genetic mutation on the X chromosome can be obtained as a carrier.
- the female carrier having a genetic mutation on the X chromosome and the male disease model pig obtained as a litter by the above (iv) are faithful to the phenotype of a human male patient born from a mother who is a carrier in humans. It can be a model animal that has been reproduced.
- a model pig having a gene mutation on the X chromosome which is obtained as a female carrier and / or the offspring by the above (iv).
- the present invention provides a genetically modified pig or a population of genetically modified pigs having a constant phenotype obtained by the method of the present invention.
- Example 1 Production of a diabetic model pig and analysis of its phenotype
- the phenotype was analyzed in detail.
- HNF-1 ⁇ P291fsinsC human HNF-1 ⁇
- An expression unit was constructed by operably linking to the porcine insulin promoter and linking human HNF-1 ⁇ P291fsinsC, poly A addition signal and chicken ⁇ -globin insulator downstream thereof to obtain a human mutant HNF-1 ⁇ expression plasmid.
- a human mutant HNF-1 ⁇ expression unit was excised from the expression plasmid, and the expression unit was introduced into an egg that had been brought into contact with the DNA on the sperm surface and matured in vitro by microinsemination-mediated gene introduction. Return the egg to the pig, obtain cells from the pig's kidneys, lungs and muscles, and transfer the nucleus into the egg cytoplasm (for details, see Kurome K. et al., Transgenic Research 15: 229-240 (2006) reference).
- FIG. 1 shows blood glucose levels and their transitions for 5 pigs.
- Each individual is a cloned individual derived from the same human HNF-1 ⁇ P291fsinsC gene-introduced cell, but as shown in FIG. 1, the blood glucose level changes greatly depending on the obtained pig, and its lifespan is also greatly different. I understood. For this reason, it became clear that further improvement is required for this diabetes model.
- Example 2 Production of a Model Pig Showing a Stable Diabetes Phenotype
- offspring obtained from the diabetes model pig obtained in Example 1 were analyzed.
- the diabetic model pig obtained in Example 1 was sexually matured by administration of insulin, sperm was collected, artificially inseminated, transplanted to an estrus-synchronized borrowed female to establish pregnancy, and a litter was obtained.
- the result of analyzing the phenotype of the resulting litter is shown in FIG.
- FIG. 2 shows the phenotype of diabetes in a representative offspring among a plurality of offspring.
- the difference in the epigenetic state of the cells used for nuclear transfer may be related to the phenotypic difference between individuals, and the reason for the stable phenotype in these offspring is the above epigenetic state Is considered to be resolved by fertilization.
- This example revealed that it is possible to stabilize the phenotype of an animal (eg, a disease model) obtained by nuclear transfer by obtaining offspring after nuclear transfer.
- an animal eg, a disease model
- Example 3 Production of Hyperammonemia Model Pig
- production of a hyperammonemia model pig was attempted.
- OTC Ornithine transcarbamylase
- MRNA encoding TALEN was introduced into male porcine fetal fibroblasts by electroporation. Thereafter, 176 clones obtained by limiting dilution of cells were analyzed for the DNA sequence targeted by TALEN, and mutations were confirmed in 43 clones (FIG. 4). Among the obtained clones, No. 69 clones had a 5 base deletion in the second exon. In the following, a model pig with hyperammonemia was prepared using this clone. In addition, No. In 69 clones, it was thought that the deletion of 5 bases produced a stop codon, thereby disrupting the OTC gene function.
- an embryo (female) was prepared from cells expressing humanized wedge orange by somatic cell cloning.
- a somatic cell clone embryo obtained using the nuclei of 69 OCT gene-disrupted clones was transplanted into a chimeric female in a estrus-synchronized estrus synchronized to produce a chimeric individual.
- the resulting chimeric individual became male.
- the resulting chimeric individuals were mated with wild-type females to obtain second generation offspring.
- female individuals had an OTC gene deficiency on one of the X chromosomes and became OTCD carriers or developed OTCD due to the influence of another trigger.
- the obtained third generation individuals faithfully reproduced the pathological conditions that excluded the epigenetic effects existing in the first generation, that is, the phenotypes of human male patients born from the mother who is a carrier. Become an animal.
- Example 4 Production of dilated cardiomyopathy model pig
- production of dilated cardiomyopathy model pig was attempted.
- ⁇ -sarcoglycan gene was disrupted as follows. Porcine SGCD exists on chromosome 16 and is thought to consist of 8 exons. In this example, a TALEN targeting the second exon containing the start codon was constructed (FIG. 5).
- MRNA encoding TALEN was introduced into male porcine fetal fibroblasts by electroporation. Thereafter, 185 clones obtained by limiting dilution of cells were analyzed for the DNA sequence targeted by TALEN, and mutations were confirmed in 67 clones (FIG. 6). Among the obtained clones, Nos. Twenty-six clones had a 4 base deletion in the second exon that created a nonsense mutation and a 1859 base deletion that greatly deleted the transmembrane domain important for SGCD function. No. Forty-nine clones had a 5 base deletion in the second exon that created a nonsense mutation and a 713 base deletion that completely deleted exon 2. In these clones, it was considered that the function of the SGCD gene was disrupted.
- somatic cell clone embryos were obtained in the same manner as in Example 3 to obtain SGCD gene knockout pigs.
- These offspring developed symptoms characteristic of dilated cardiomyopathy 4 weeks after birth. The systemic symptoms of the offspring were more severe than those estimated from normal SGCD gene deficiency patients, and some individuals died of heart failure in the first few weeks of life. When a plurality of offspring were analyzed, their phenotypes differed greatly from one individual to another (Table 3).
- Example 3 In the same manner as in Example 3, the obtained embryo and a somatic cell clone embryo obtained from cells expressing wavira orange were transplanted into a born-established female in an estrus-synchronized state to produce a chimeric individual. The resulting chimeric individual became male. However, this male died before reaching sexual maturity. The cause of death was presumed to be arrhythmia due to stress associated with administration of drugs such as sedatives. Testicular tissue was collected and stored frozen before the male died.
- testis tissue that has been cryopreserved can be transplanted subcutaneously into immunodeficient mice to obtain fertilized sperm. Therefore, if the obtained sperm is fertilized with a wild-type female unfertilized egg and a second-generation offspring is obtained, a female having an SGCD gene deficiency on one of the chromosomes among the offspring should be obtained. is there. Such females serve as carriers of SGCD gene deficiency.
- male individuals with SGCD gene deficiency are model animals that faithfully reproduce the phenotype of a human male patient born from a mother who is a carrier with SGCD gene deficiency.
- the obtained third generation individuals faithfully reproduced the pathological conditions that excluded the epigenetic effects existing in the first generation, that is, the phenotypes of human male patients born from the mother who is a carrier. Become an animal.
- the disease state of dilated cardiomyopathy also appears in the second generation pigs heterozygously deficient in the above SGCD gene.
- the second-generation pig is considered to exhibit a pathology closer to that of human familial dilated cardiomyopathy patients because the somatic epigenetic modifications have been reset.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
(1)遺伝子改変された疾患モデルブタを作製する方法であって、
(a)遺伝子改変された細胞の核を用いて卵細胞質に核移植することと、
(b)得られたクローン胚を雌ブタの胎内で発生させて産仔を得ることと、
(c)得られた産仔を交配させて、または有性生殖に供して、該遺伝子改変された更なる産仔を疾患モデルブタとして得ることと、
を含む、方法。
(2) 疾患モデルブタが、糖尿病、高アンモニア血症および拡張型心筋症からなる群から選択される疾患のモデルブタである、上記(1)に記載の方法。
(3)疾患モデルブタが、糖尿病モデル動物であり、上記(a)において用いられる細胞が、HNF-1αのドミナントネガティブ型変異体を導入することによって遺伝子改変された細胞である、上記(2)に記載の方法。
(4)疾患モデルブタが、拡張型心筋症モデルブタである、上記(2)に記載の方法。
(5)疾患の表現型が優性形質である、上記(2)~(4)のいずれかに記載の方法。
(6)上記(1)~(5)のいずれかに記載の方法により得られる疾患モデルブタ。
(7)致死性の遺伝子疾患モデルブタを作製する方法であって、
(i)遺伝子改変された細胞の核を用いて卵細胞質に核移植することと、
(ii)核移植して得られたクローン胚を、遺伝子疾患を発症しないブタの胚とキメラ状態にして、雌ブタの胎内で発生させて産仔を得ることと、
(iii)得られた産仔を交配させて、または得られた産仔の生殖細胞を有性生殖に供して、該遺伝子改変を有する雌の産仔を得ることと、
(iv)得られた雌の産仔を雄のブタと交配させて、または有性生殖に供して、致死性の遺伝子疾患モデルブタを得ることと
を含む、方法。
(8)致死性の遺伝子疾患が、高アンモニア血症である、上記(7)に記載の方法。
(9)致死性の遺伝子疾患が、拡張型心筋症である、上記(7)に記載の方法。
(10)上記(7)~(9)のいずれかに記載の方法により得られる致死性の遺伝子疾患モデルブタ。
(11)オルニチントランスカルバミラーゼ遺伝子の遺伝子機能が破壊された、高アンモニア血症のモデルブタ。
(12)オルニチントランスカルバミラーゼ遺伝子の第2エキソンの一部が欠失し、これによりナンセンス変異が生じた、高アンモニア血症のモデルブタ。
(13)遺伝子機能が破壊されたオルニチントランスカルバミラーゼ遺伝子を有する細胞と、野生型のオルニチントランスカルバミラーゼ遺伝子を有する細胞を体細胞キメラ状態で有する、遺伝子改変ブタ。
(14)上記(13)に記載のブタから有性生殖により得られる、遺伝子機能が破壊されたオルニチントランスカルバミラーゼ遺伝子をヘテロで有する雌ブタ。
(15)上記(14)に記載の雌ブタから有性生殖により得られる、高アンモニア血症のモデルである雄ブタ。
(16)γ-サルコグリカン遺伝子の遺伝子機能が破壊された、拡張型新緊張のモデルブタ。
(17)γ-サルコグリカン遺伝子の第2エキソンの一部が欠失し、これによりナンセンス変異が生じた、拡張型心筋症のモデルブタ。
(18)遺伝子機能が破壊されたγ-サルコグリカン遺伝子を有する細胞と、野生型のγ-サルコグリカン遺伝子を有する細胞を体細胞キメラ状態で有する、遺伝子改変ブタ。
(19)上記(18)に記載のブタから有性生殖により得られる、遺伝子機能が破壊されたγ-サルコグリカン遺伝子をヘテロで有する雌ブタ。
(20)上記(19)に記載の雌ブタから有性生殖により得られ、遺伝子機能が破壊されたγ-サルコグリカン遺伝子をホモで有する、拡張型心筋症のモデルである雄ブタ。
(21)以下の方法により得られる生殖腺または生殖細胞:
(i)遺伝子改変された細胞の核を用いて卵細胞質に核移植することと、
(ii)核移植して得られたクローン胚を、遺伝子疾患を発症しないブタの胚とキメラ状態にして、雌ブタの胎内で発生させて産仔を得ることと、
(iii-a)得られた産仔を成長させ、生殖腺または生殖細胞を得ることとを含む、方法。
(22)遺伝子改変された細胞が、オルニチントランスカルバミラーゼ遺伝子の遺伝子機能が破壊された細胞であるか、または、γ-サルコグリカン遺伝子の遺伝子機能が破壊された細胞である、上記(21)に記載の生殖腺または生殖細胞。
遺伝子改変された疾患モデルブタを作製する方法であって、
(a)遺伝子改変された細胞の核を用いて卵細胞質に核移植することと、
(b)得られたクローン胚を雌ブタの胎内で発生させて産仔を得ることと、
(c)得られた産仔を交配させて、または有性生殖に供して、該遺伝子改変された更なる産仔を疾患モデルブタとして得ることと、
を含む、方法が提供される。
細胞は、周知の遺伝子改変技術により改変することができる。
得られたクローン胚は、雌ブタの胎内で発生させることができ、これにより遺伝子改変された細胞からなる産仔(遺伝子改変ブタ)を得ることができる。雌ブタは発情同期化させてからクローン胚を子宮に導入することにより、その胎内で妊娠を成立させることができ、クローン胚を発生させることにより、産仔を得ることができる。(b)で得られるブタを第一世代のブタということがある。
産仔が性成熟可能な場合には、性成熟させてから交配させるか、有性生殖に供することにより、遺伝子改変された次世代のブタ(「第二世代のブタ」ということがある)を得ることができる。また、産仔が性成熟前に致死となる場合には、周知の方法により生殖細胞(精子、卵子およびそれらの前駆細胞)または生殖腺を得てから人工授精または体外受精等の方法により、遺伝子改変された次世代のブタを得ることができる。
(c)得られた産仔を交配させて、または有性生殖に供して、該遺伝子改変された更なる産仔を、遺伝子変異をヘテロで有する産仔(すなわち、劣性遺伝子変異のキャリア)として得ること、
とし、その後、さらに
(d)劣性遺伝子変異のキャリア同士を有性生殖に供して、遺伝子変異をホモで有する産仔を疾患モデルブタとして得ること
ができる。
(c)得られた産仔を交配させて、または有性生殖に供して、該遺伝子改変された更なる産仔を、遺伝子変異をヘテロで有する産仔(すなわち、劣性遺伝子変異のキャリア)として得ること、
とし、その後、さらに
(d)劣性遺伝子変異のキャリア同士を有性生殖に供して、X染色体上の遺伝子変異を有する雌のキャリアを有性生殖に供して、雄の産仔を疾患モデルブタとして得ること
ができる。
遺伝子疾患モデルブタを作製する方法であって、
(i)遺伝子改変された細胞の核を用いて卵細胞質に核移植することと、
(ii)核移植して得られたクローン胚を、遺伝子疾患を発症しないブタの胚と混合してキメラ状態にして、雌ブタの胎内で発生させて産仔を得ることと、
(iii)得られた産仔を交配させて、または得られた産仔の生殖細胞を有性生殖に供して、該遺伝子改変を有する産仔を得ることと、
を含む、方法が提供される。
(i)は、上記(a)と同じであるから、そちらを参照し、ここでの説明は省略する。
体細胞を用いた核移植(体細胞クローニング)により得られた胚は、遺伝子疾患を発症しないブタの胚と混合し、キメラ状態にして、雌ブタの胎内で発生させて産仔を得ることができる。胚の混合は、初期分割期(1細胞期~桑実期)の胚を用いる場合には、割球を他方の胚に混合し、胚盤胞期の胚を用いる場合には、内部細胞塊を他方の胚に混合することができる。該遺伝子疾患を発症しないブタの胚は、ある態様では、標識された細胞から体細胞クローニングで得られたクローン胚とすることができる。この具体的な態様において、標識は、特に限定されないが例えば、クサビラオレンジおよび緑色蛍光タンパク質(GFP)などの蛍光タンパク質による標識とすることができる。キメラ状態の胚は、例えば、発情同期化した借り腹雌に移植すれば、発生し、キメラ個体として産仔を得ることができる。本発明では、このようにして得られるキメラ個体をも提供する。
工程(x):致死性の遺伝子変異を有する核移植胚(クローン胚)と、該遺伝子変異を有さない核移植胚または健常な胚をそれぞれ作製する。ここで、いずれの核移植胚も、一旦凍結保存されたものでもあってもよい。
工程(y):初期分割期(1細胞期~桑実期)の一方の胚に、同じ発生段階の他方の胚から得た割球を注入すると、透明帯内部にて両者の割球を凝集させ、キメラ状態を生じさせ得る。工程(y)では、胚盤胞期の胚を用いることもできる。胚盤胞期の胚を用いる際には、一方の胚盤胞に他方の胚から分離した内部細胞塊の全体あるいは一部を注入することによって、キメラ状態を生じさせ得る。
工程(z):数時間から数日程度の体外培養によってキメラ状態の進行を確認した後、借り腹雌の卵管あるいは子宮内に移植して発育させる。
(iii)は、上記(c)と同じであるから、上記(c)を参照することとし、ここでの説明は省略する。産仔が、疾患を発症する場合には、産仔は疾患モデルブタとして得られることとなる。一方で、産仔が疾患を発症しない場合には、産仔はキャリアとして得られることとなる。本発明では、遺伝子変異を有するキャリア(例えば、雌または雄)をも提供する。(iii)により得られた産仔がキャリアとなった場合には、さらに以下(iv)を行うことができる。
(iv)は上記(d)と同じである。すなわち、劣性遺伝子変異のキャリア同士を有性生殖に供して、または、X染色体上の遺伝子変異を有する雌のキャリアを有性生殖に供して、遺伝子変異をホモで有する産仔を、疾患モデルブタとして得ることができる。
本実施例では、Umeyama K. et al., Transgenic Res. 18:697-706 (2009)の記載に基づき、糖尿病モデルブタの作製を試み、その表現型を詳細に分析した。
本実施例では、実施例1で得られた糖尿病モデルブタから得られた産仔を分析した。
本実施例では、高アンモニア血症モデルブタの作製を試みた。
本実施例では、拡張型心筋症モデルブタの作製を試みた。
Claims (22)
- 遺伝子改変された疾患モデルブタを作製する方法であって、
(a)遺伝子改変された細胞の核を用いて卵細胞質に核移植することと、
(b)得られたクローン胚を雌ブタの胎内で発生させて産仔を得ることと、
(c)得られた産仔を交配させて、または有性生殖に供して、該遺伝子改変された更なる産仔を疾患モデルブタとして得ることと、
を含む、方法。 - 疾患モデルブタが、糖尿病、高アンモニア血症および拡張型心筋症からなる群から選択される疾患のモデルブタである、請求項1に記載の方法。
- 疾患モデルブタが、糖尿病モデル動物であり、上記(a)において用いられる細胞が、HNF-1αのドミナントネガティブ型変異体を導入することによって遺伝子改変された細胞である、請求項2に記載の方法。
- 疾患モデルブタが、拡張型心筋症モデルブタである、請求項2に記載の方法。
- 疾患の表現型が優性形質である、請求項2~4のいずれか一項に記載の方法。
- 請求項1~5のいずれか一項に記載の方法により得られる疾患モデルブタ。
- 致死性の遺伝子疾患モデルブタを作製する方法であって、
(i)遺伝子改変された細胞の核を用いて卵細胞質に核移植することと、
(ii)核移植して得られたクローン胚を、遺伝子疾患を発症しないブタの胚とキメラ状態にして、雌ブタの胎内で発生させて産仔を得ることと、
(iii)得られた産仔を交配させて、または得られた産仔の生殖細胞を有性生殖に供して、該遺伝子改変を有する雌の産仔を得ることと、
(iv)得られた雌の産仔を雄のブタと交配させて、または有性生殖に供して、致死性の遺伝子疾患モデルブタを得ることと
を含む、方法。 - 致死性の遺伝子疾患が、高アンモニア血症である、請求項7に記載の方法。
- 致死性の遺伝子疾患が、拡張型心筋症である、請求項7に記載の方法。
- 請求項7~9のいずれか一項に記載の方法により得られる致死性の遺伝子疾患モデルブタ。
- オルニチントランスカルバミラーゼ遺伝子の遺伝子機能が破壊された、高アンモニア血症のモデルブタ。
- オルニチントランスカルバミラーゼ遺伝子の第2エキソンの一部が欠失し、これによりナンセンス変異が生じた、高アンモニア血症のモデルブタ。
- 遺伝子機能が破壊されたオルニチントランスカルバミラーゼ遺伝子を有する細胞と、野生型のオルニチントランスカルバミラーゼ遺伝子を有する細胞を体細胞キメラ状態で有する、遺伝子改変ブタ。
- 請求項13に記載のブタから有性生殖により得られる、遺伝子機能が破壊されたオルニチントランスカルバミラーゼ遺伝子をヘテロで有する雌ブタ。
- 請求項14に記載の雌ブタから有性生殖により得られる、高アンモニア血症のモデルである雄ブタ。
- γ-サルコグリカン遺伝子の遺伝子機能が破壊された、拡張型心筋症のモデルブタ。
- γ-サルコグリカン遺伝子の第2エキソンの一部が欠失し、これによりナンセンス変異が生じた、拡張型心筋症のモデルブタ。
- 遺伝子機能が破壊されたγ-サルコグリカン遺伝子を有する細胞と、野生型のγ-サルコグリカン遺伝子を有する細胞を体細胞キメラ状態で有する、遺伝子改変ブタ。
- 請求項18に記載のブタから有性生殖により得られる、遺伝子機能が破壊されたγ-サルコグリカン遺伝子をヘテロで有する雌ブタ。
- 請求項19に記載の雌ブタから有性生殖により得られ、遺伝子機能が破壊されたγ-サルコグリカン遺伝子をホモで有する、拡張型心筋症のモデルである雄ブタ。
- 以下の方法により得られる生殖腺または生殖細胞:
(i)遺伝子改変された細胞の核を用いて卵細胞質に核移植することと、
(ii)核移植して得られたクローン胚を、遺伝子疾患を発症しないブタの胚とキメラ状態にして、雌ブタの胎内で発生させて産仔を得ることと、
(iii-a)得られた産仔を成長させ、生殖腺または生殖細胞を得ることと
を含む、方法。 - 遺伝子改変された細胞が、オルニチントランスカルバミラーゼ遺伝子の遺伝子機能が破壊された細胞であるか、または、γ-サルコグリカン遺伝子の遺伝子機能が破壊された細胞である、請求項21に記載の生殖腺または生殖細胞。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017503736A JP6929527B2 (ja) | 2015-03-04 | 2016-03-04 | 安定した表現型を示す疾患モデルブタおよびその作製方法 |
US15/553,934 US11246299B2 (en) | 2015-03-04 | 2016-03-04 | Disease model pig exhibiting stable phenotype, and production method thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015041923 | 2015-03-04 | ||
JP2015-041923 | 2015-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016140353A1 true WO2016140353A1 (ja) | 2016-09-09 |
Family
ID=56848231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/056865 WO2016140353A1 (ja) | 2015-03-04 | 2016-03-04 | 安定した表現型を示す疾患モデルブタおよびその作製方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11246299B2 (ja) |
JP (3) | JP6929527B2 (ja) |
WO (1) | WO2016140353A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018057790A1 (en) * | 2016-09-21 | 2018-03-29 | Recombinetics, Inc. | Animal models for cardiomyopathy |
CN113450876A (zh) * | 2017-05-23 | 2021-09-28 | 毕节市农业科学研究所 | 找出每个生物个体中所缺失的有利遗传物质的方法及在濒危群体中的恢复方法 |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001231557A (ja) * | 2000-02-18 | 2001-08-28 | Teruhiko Toyooka | 拡張型心筋症の遺伝子治療剤 |
JP2003509031A (ja) * | 1999-09-13 | 2003-03-11 | ユニバシティ オブ マサチューセッツ、ア パブリック インスチチユーション オブ ハイアー エデュケイション オブ ザ コモンウエルス オブ マサチューセッツ、アズ リプリゼンテッド バイ イッツ アマースト キャンパス | ドナー細胞又は分化細胞からの核を使用する豚のクローニング並びに多能性豚の産生 |
JP2003510072A (ja) * | 1999-09-30 | 2003-03-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 遺伝子発現を改変するための組成物および方法 |
JP2004073189A (ja) * | 1998-11-02 | 2004-03-11 | Gtc Biotherapeutics Inc | トランスジェニック哺乳動物およびクローン哺乳動物 |
JP2010110254A (ja) * | 2008-11-05 | 2010-05-20 | Primetech Kk | 共通サイトカイン受容体γ鎖遺伝子ノックアウトブタ |
JP2010520751A (ja) * | 2007-03-07 | 2010-06-17 | オーフス ユニバーシティ | 乾癬のブタモデル |
JP2011506922A (ja) * | 2007-12-05 | 2011-03-03 | キングス カレッジ ロンドン | 方法及び組成物 |
JP2011223976A (ja) * | 2010-04-22 | 2011-11-10 | Oregon Health & Science Univ | フマリルアセト酢酸ヒドロラーゼ(fah)欠損性ブタおよびその使用 |
JP2011229456A (ja) * | 2010-04-27 | 2011-11-17 | Primetech Kk | 血友病aモデルブタの作出 |
JP2013118859A (ja) * | 2011-12-08 | 2013-06-17 | Primetech Kk | 高脂血症モデルブタ |
JP2013215615A (ja) * | 2004-03-17 | 2013-10-24 | Revivicor Inc | 機能的α1,3ガラクトシルトランスフェラーゼを欠く動物に由来する組織生成物 |
US20140123330A1 (en) * | 2012-10-30 | 2014-05-01 | Recombinetics, Inc. | Control of sexual maturation in animals |
WO2014085501A1 (en) * | 2012-11-28 | 2014-06-05 | Guochun Gong | Cloned non-human animals free of selective markers |
JP2015002719A (ja) * | 2013-06-21 | 2015-01-08 | 全国農業協同組合連合会 | 免疫不全ブタ |
WO2015155904A1 (ja) * | 2014-04-07 | 2015-10-15 | 学校法人自治医科大学 | 遺伝子ノックアウトブタ |
WO2016029919A1 (en) * | 2014-08-28 | 2016-03-03 | Aarhus Universitet | Pig model for diabetes |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7291764B1 (en) | 1997-01-10 | 2007-11-06 | University of Massachusetts, a Public Institution of Higher Education of the Commonwealth of Massachusetts, as Represented by its Amherst Campus, Office of Vice Chancellor for Research at Amherst | Cloning pigs using non-quiescent differentiated donor cells or nuclei |
US5945577A (en) | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
US6235969B1 (en) | 1997-01-10 | 2001-05-22 | University Of Massachusetts | Cloning pigs using donor nuclei from non-quiescent differentiated cells |
US20030177513A1 (en) | 1998-11-02 | 2003-09-18 | Yann Echelard | Transgenic and cloned mammals |
JP4036356B2 (ja) * | 2000-08-03 | 2008-01-23 | 独立行政法人農業・食品産業技術総合研究機構 | クローン豚の作出方法 |
JP2002238562A (ja) | 2000-12-28 | 2002-08-27 | Chemo Sero Therapeut Res Inst | 遺伝子組換えウサギ及び体細胞核移植を用いた当該遺伝子組換えウサギの作製方法 |
JP2007082454A (ja) | 2005-09-21 | 2007-04-05 | Bios Ikagaku Kenkyusho:Kk | 糖尿病発症トランスジェニックブタ及びその作出方法 |
JP4774514B2 (ja) * | 2005-11-22 | 2011-09-14 | 国立大学法人 鹿児島大学 | 超音波による卵子またはクローン胚の活性化方法ならびに該方法により活性化したクローン胚からのクローン動物の作出 |
JP4830139B2 (ja) * | 2006-03-10 | 2011-12-07 | 学校法人明治大学 | クローン胚の作製方法 |
JP2008121964A (ja) | 2006-11-10 | 2008-05-29 | Mitsubishi Electric Corp | 住宅構造及び住宅の構築方法 |
EP2134848A2 (en) | 2007-03-07 | 2009-12-23 | Aarhus Universitet | Pig model for breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex |
AU2012255744A1 (en) * | 2011-05-16 | 2014-01-09 | The Curators Of The University Of Missouri | Porcine reproductive and respiratory syndrome virus resistant animals |
-
2016
- 2016-03-04 WO PCT/JP2016/056865 patent/WO2016140353A1/ja active Application Filing
- 2016-03-04 US US15/553,934 patent/US11246299B2/en active Active
- 2016-03-04 JP JP2017503736A patent/JP6929527B2/ja active Active
-
2021
- 2021-07-27 JP JP2021122062A patent/JP2021176317A/ja active Pending
-
2023
- 2023-06-16 JP JP2023098843A patent/JP2023116719A/ja active Pending
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004073189A (ja) * | 1998-11-02 | 2004-03-11 | Gtc Biotherapeutics Inc | トランスジェニック哺乳動物およびクローン哺乳動物 |
JP2003509031A (ja) * | 1999-09-13 | 2003-03-11 | ユニバシティ オブ マサチューセッツ、ア パブリック インスチチユーション オブ ハイアー エデュケイション オブ ザ コモンウエルス オブ マサチューセッツ、アズ リプリゼンテッド バイ イッツ アマースト キャンパス | ドナー細胞又は分化細胞からの核を使用する豚のクローニング並びに多能性豚の産生 |
JP2003510072A (ja) * | 1999-09-30 | 2003-03-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 遺伝子発現を改変するための組成物および方法 |
JP2001231557A (ja) * | 2000-02-18 | 2001-08-28 | Teruhiko Toyooka | 拡張型心筋症の遺伝子治療剤 |
JP2013215615A (ja) * | 2004-03-17 | 2013-10-24 | Revivicor Inc | 機能的α1,3ガラクトシルトランスフェラーゼを欠く動物に由来する組織生成物 |
JP2010520751A (ja) * | 2007-03-07 | 2010-06-17 | オーフス ユニバーシティ | 乾癬のブタモデル |
JP2011506922A (ja) * | 2007-12-05 | 2011-03-03 | キングス カレッジ ロンドン | 方法及び組成物 |
JP2010110254A (ja) * | 2008-11-05 | 2010-05-20 | Primetech Kk | 共通サイトカイン受容体γ鎖遺伝子ノックアウトブタ |
JP2011223976A (ja) * | 2010-04-22 | 2011-11-10 | Oregon Health & Science Univ | フマリルアセト酢酸ヒドロラーゼ(fah)欠損性ブタおよびその使用 |
JP2011229456A (ja) * | 2010-04-27 | 2011-11-17 | Primetech Kk | 血友病aモデルブタの作出 |
JP2013118859A (ja) * | 2011-12-08 | 2013-06-17 | Primetech Kk | 高脂血症モデルブタ |
US20140123330A1 (en) * | 2012-10-30 | 2014-05-01 | Recombinetics, Inc. | Control of sexual maturation in animals |
WO2014085501A1 (en) * | 2012-11-28 | 2014-06-05 | Guochun Gong | Cloned non-human animals free of selective markers |
JP2015002719A (ja) * | 2013-06-21 | 2015-01-08 | 全国農業協同組合連合会 | 免疫不全ブタ |
WO2015155904A1 (ja) * | 2014-04-07 | 2015-10-15 | 学校法人自治医科大学 | 遺伝子ノックアウトブタ |
WO2016029919A1 (en) * | 2014-08-28 | 2016-03-03 | Aarhus Universitet | Pig model for diabetes |
Non-Patent Citations (4)
Title |
---|
DAVIS, B. T. ET AL.: "Targeted Disruption of LDLR Causes Hypercholesterolemia and Atherosclerosis in Yucatan Miniature Pigs", PLOS ONE, vol. 4, pages e93457, ISSN: 1932-6203 * |
HICKEY, R. D. ET AL.: "Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver disease", STEM CELL RESEARCH, vol. 1, 13 July 2014 (2014-07-13), pages 144 - 153, XP028863277, ISSN: 1873-5061, DOI: doi:10.1016/j.scr.2014.05.003 * |
HITOMI MATSUNARI ET AL.: "Idenshi Kaihen Shikkan Model Buta no Kaihatsu ni Okeru Haibanho Hokanho no Igi: Shinseiji Chishisei Keishitsu no Kyusai to Yusei Seishoku eno Hashiwatashi", DAI 108 KAI THE JAPANESE SOCIETY OF ANIMAL REPRODUCTION TAIKAI KOEN YOSHISHU, 15 September 2015 (2015-09-15) * |
UMEYAMA, K. ET AL.: "Dominant-negative mutant hepatocyte nuclear factor 1alpha induces diabetes in transgenic-cloned pigs", TRANSGENIC RESEARCH, vol. 18, 2009, pages 697 - 706, XP019734279, ISSN: 1573-9368, DOI: doi:10.1007/s11248-009-9262-3 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018057790A1 (en) * | 2016-09-21 | 2018-03-29 | Recombinetics, Inc. | Animal models for cardiomyopathy |
CN113450876A (zh) * | 2017-05-23 | 2021-09-28 | 毕节市农业科学研究所 | 找出每个生物个体中所缺失的有利遗传物质的方法及在濒危群体中的恢复方法 |
Also Published As
Publication number | Publication date |
---|---|
US20180103619A1 (en) | 2018-04-19 |
US11246299B2 (en) | 2022-02-15 |
JP2021176317A (ja) | 2021-11-11 |
JPWO2016140353A1 (ja) | 2018-01-25 |
JP2023116719A (ja) | 2023-08-22 |
JP6929527B2 (ja) | 2021-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6878482B2 (ja) | 大型家畜の接合体における標的化ゲノム編集 | |
CN108660161B (zh) | 基于CRISPR/Cas9技术的制备无嵌合基因敲除动物的方法 | |
Li et al. | Cloned ferrets produced by somatic cell nuclear transfer | |
Rivera-Pérez et al. | Goosecoid is not an essential component of the mouse gastrula organizer but is required for craniofacial and rib development | |
JP2022033771A (ja) | 改変cd163遺伝子を有する病原体抵抗性動物 | |
CN109072218A (zh) | 基因修饰非人生物、卵细胞、受精卵以及目的基因的修饰方法 | |
KR20180091821A (ko) | 유전적 상보성에 의한 인간화 car t-세포 및 혈소판의 조작방법 | |
JP6998656B2 (ja) | lincRNA欠失非ヒト動物 | |
JP2023116719A (ja) | 安定した表現型を示す疾患モデルブタおよびその作製方法 | |
KR102631856B1 (ko) | 변형된 cd163 유전자를 갖는 병원균-내성 동물 | |
US20190223417A1 (en) | Genetically modified animals having increased heat tolerance | |
US20070245424A1 (en) | Method for producing germ-line chimeric animal | |
EP4335926A2 (en) | Nanos knock-out that ablates germline cells | |
CN108882696A (zh) | 通过遗传互补对人源化肾脏的工程改造 | |
US20240041010A1 (en) | Generation of surrogate sires and dams by ablation of endogenous germline | |
CN111705063A (zh) | Asgr1突变基因及其在制备哺乳动物肝损伤敏感模型中的应用 | |
WO2020210556A1 (en) | Sterile fish | |
JP2021526353A (ja) | ウイルス感染からブタ胎児を保護するための方法 | |
CN113615638B (zh) | 一种性早熟动物模型的构建方法及其应用 | |
JP2023175832A (ja) | 融合タンパク質、核酸、細胞及び動物の製造方法 | |
Huitema | CRISPR-Cas9 genome editing in the livestock industry: A promising addition to current breeding programs | |
GB2617296A (en) | Transgenic animal having modified myostatin gene | |
WO2024092216A2 (en) | Methods and compositions regarding modulation of poultry genes | |
JP2004180641A (ja) | RNAi表現型を有する非ヒト哺乳動物の作製方法 | |
KR20240108545A (ko) | 바이러스에 의한 감염으로부터 돼지 태아를 보호하는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16759045 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017503736 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15553934 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16759045 Country of ref document: EP Kind code of ref document: A1 |